Pricing Sign in

PROK

Prokidneydistress 5/10 · elevated risk

$1.51-1%today-67% from 52w high

prokidney.com231 employeesFounded 2015Winston-Salem, NCBiotechnology

Metabolic / Obesity 1

Lead: chronic kidney disease

Revenue

pre-revenue

Liquidity

$102M

Runway

0.8 yrs

Shares 1y

—

Price & events

-30.7% over 6M

CatalystRating changeDilutionFinancingdashed = today

-1.2%

1D

-6.1%

1W

-16.0%

1M

-24.4%

3M

-30.4%

6M

-53.1%

1Y

-35.4%

2Y

-84.8%

5Y

-85.1%

All

Overview

Volume: 70.94K
52 Week Range: $1.51 – $4.54
Float Shares: 156.76M
Short %: 12.81%
% Held by Insiders: 47.30%
% Held by Institutions: 24.40%
RVOL: 0.05x
Beta: 1.68

Pipeline stages · 1 programs

Renal Autologous Cell Therapy (REACT/ rilparencel)

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2029-12

Pipeline · 2 trials · 1 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2029-12 Estimated 50% readout ~2030-02-14	Phase 3	Renal Autologous Cell Therapy (REACT/ rilparencel)	Type 2 Diabetes Mellitus, Chronic Kidney Diseases	—	recruiting
2025-05-20	Phase 2	Renal Autologous Cell Therapy (REACT)	Chronic Kidney Diseases, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus	53	completed

Catalyst news & presentations · 11

second half of 2029Guided 55%readoutPhase 3rilparencel · topline data readout of confirmatory endpoint composite time-to-eventSEC 8-K
2H 2027Guided 55%regulatory submissionFiled (NDA/BLA)rilparencel · BLA submission to FDA for rilparencel.SEC 8-K
by Q3 2027Guided 70%readoutPhase 3rilparencel · Topline data from REGEN-006 (PROACT 1) trialSEC 8-K
second quarter of 2027Guided 70%readoutPhase 3rilparencel · topline data readout of surrogate endpoint eGFR slopeSEC 8-K
2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
mid-2026enrollment completesecondaryPhase 3rilparencel · Complete enrollment for accelerated approval efficacy analysis.SEC 8-K
summer 2025readoutFDA Type B meeting to confirm eGFR slope as surrogate endpoint for accelerated approvalSEC 8-K
ASN 2025 Kidney Weekconferencedata presentationsecondaryPhase 2rilparencel · Late-breaking clinical trial presentation of full REGEN-007 resultsSEC 8-K
2025-07-15fda agreementrilparencel · FDA confirmed eGFR slope as surrogate endpoint for accelerated approval of rilparencel; Phase 3 PROACT 1 study can support both accelerated and full approval.SEC 8-K
2025-07-14withdrawalMutually terminated prior Open Market Sale Agreement dated January 19, 2024.SEC 8-K
2025-07-14partnershipEntered into Open Market Sale Agreement with Jefferies LLC for up to $200M at-the-market offering.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: — · 0 offerings/1y · 0 PIPEs

2025-11-18EFFECTshelf_effective
2025-10-178-Kmaterial_agreement
2025-07-148-Kmaterial_agreement
2025-07-14424B5offering
2025-07-07EFFECTshelf_effective
2025-07-07EFFECTshelf_effective
2025-04-28424B3offering

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Wall St ratings

no consensus

2026-05-18HC Wainwright & Co.Buy
2025-12-16HC Wainwright & Co.Buy
2025-07-15UBSBuy
2025-07-14GuggenheimBuy
2025-07-09CitigroupBuy
2025-06-30B of A SecuritiesNeutral → Underperform

Competitors — chronic kidney disease

LLYELI LILLY & Co$1094.4B · D3
IRONDisc Medicine, Inc.$2.8B · D1
MLYSMineralys Therapeutics, Inc.$2.1B · D6
AKBAAkebia Therapeutics, Inc.$329M · D0
UNCYUnicycive Therapeutics, Inc.$147M · D6
REVBREVELATION BIOSCIENCES, INC.$4M · D5
REVBWREVELATION BIOSCIENCES, INC.$33,222 · D6
BAYRY— · D2
AZNASTRAZENECA PLC— · D3
NONOFNOVO NORDISK A S— · D2

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.